Thymosin Alpha-1: immune-modulating thymic peptide research overview

Thymosin alpha-1 (Tα1; INN: thymalfasin) is a 28-amino acid peptide first isolated from thymosin fraction 5 — a calf-thymus extract — by Allan Goldstein and colleagues at George Washington University in the mid-1970s. It is the amino-terminal fragment of prothymosin alpha and is naturally secreted by thymic epithelial cells. Commercially, it is marketed as Zadaxin by SciClone Pharmaceuticals, and it has received regulatory approval in more than 35 countries for the treatment of chronic hepatitis B, chronic hepatitis C, and immune support in oncology settings. In the United States, the FDA has not approved Zadaxin for any therapeutic indication, but the agency has granted orphan-drug designation for thymalfasin in several conditions. This guide reviews the compound's biology, clinical evidence, pharmacokinetics, and regulatory status.

What is thymosin alpha-1?

Thymosin alpha-1 is a 28-amino acid acetylated polypeptide (molecular weight approximately 3,108 Da) with the sequence Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn. The N-terminus bears an acetyl group that is critical for biological activity. Allan Goldstein's laboratory at George Washington University and later at George Mason University characterized the biological activity of thymosin fraction 5 and its components over several decades. Ernesto Garaci at the Istituto Superiore di Sanità in Rome contributed extensively to the characterization of thymosin alpha-1's immunological properties, particularly its role in hepatitis C combination therapy and cancer immunotherapy. The synthetic form, thymalfasin, is produced by solid-phase peptide synthesis and is chemically identical to the endogenous peptide.

In the United States, the FDA has granted orphan-drug designation for thymalfasin in malignant melanoma, hepatocellular carcinoma, DiGeorge anomaly with immune defects, and chronic active hepatitis B. These designations facilitate drug development incentives but do not constitute therapeutic approval; no FDA-approved indication for Zadaxin exists. In contrast, Zadaxin is approved in more than 35 countries — including Italy, China, the Philippines, Pakistan, and several Asian and Latin American markets — for hepatitis B and hepatitis C treatment and for immune support in oncology patients.

Mechanism of action

Thymosin alpha-1 exerts its immunological effects primarily through interaction with Toll-like receptors (TLRs), particularly TLR2 and TLR9, on plasmacytoid dendritic cells and other immune cells. Activation of these pattern-recognition receptors triggers downstream signaling through MyD88, NF-κB, and IRF7 pathways, promoting interferon production — especially type I interferons (IFN-α/β) — and enhancing antigen presentation. At the cellular level, the peptide promotes the maturation and differentiation of naïve T lymphocytes into functional CD4+ and CD8+ effector and memory subsets, and directly activates natural killer (NK) cells. In the context of viral infection, these effects translate to enhanced cytotoxic responses against virally infected cells.

Mechanistically, thymosin alpha-1 is considered an immunomodulator rather than an immunostimulant in the narrow sense: it appears to shift the immune balance toward type 1 immunity (Th1-polarized responses, characterized by IFN-γ and IL-2 production) and away from Th2-polarized or tolerogenic states. This profile makes it of interest in settings where antiviral or antitumor immunity is suppressed, and also potentially in sepsis and secondary immunodeficiency. Comprehensive mechanism reviews have been published by Tuthill et al. (Ann N Y Acad Sci, 2010; PMID 20738318) and by the PMC comprehensive review (PMC7747025).

What the research shows

The most extensively studied clinical applications of thymosin alpha-1 are chronic hepatitis B and chronic hepatitis C. In hepatitis B, both monotherapy and combination regimens with interferon-alpha have been evaluated. Clinical trials found complete virological response rates of approximately 36–41% with Tα1 1.6 mg subcutaneous injection twice weekly, comparable to or modestly superior to interferon monotherapy with a more favorable tolerability profile. These results supported regulatory approvals in multiple Asian markets where hepatitis B prevalence is high.

In hepatitis C, the pivotal trial was a randomized, placebo-controlled, double-blind study of combination therapy with thymosin alpha-1 and interferon-alpha for chronic hepatitis C, published in Hepatology in 1998 (Zeuzem et al., PMID 9537454). This trial demonstrated that the combination of Tα1 plus interferon produced significantly higher sustained virological response rates compared to interferon alone. A meta-analysis by Sherman and colleagues (cited in PubMed record 15992078) further supported the superiority of the combination versus interferon monotherapy. However, the emergence of direct-acting antiviral agents for hepatitis C — achieving cure rates above 95% — has rendered thymosin alpha-1 largely obsolete for hepatitis C treatment, and it is no longer a standard-of-care option for that indication in well-resourced settings.

Beyond hepatitis, thymosin alpha-1 has been investigated in cancer immunotherapy — particularly as an adjunct to chemotherapy in non-small-cell lung cancer and hepatocellular carcinoma — and in immune support for sepsis patients in the intensive care setting. A well-publicized Chinese ICU trial during the early COVID-19 pandemic period examined thymosin alpha-1 as an immune adjunct in critically ill patients. The evidence base in oncology and sepsis, while suggesting potential immune-modulating benefits, consists largely of smaller single-center trials and does not yet support broad guideline recommendations in major Western markets. The comprehensive PMC review (PMC7747025) provides the most thorough synthesis of the heterogeneous clinical trial literature through 2020.

Pharmacokinetics

Thymosin alpha-1 is administered by subcutaneous injection; oral bioavailability is negligible owing to proteolytic degradation in the gastrointestinal tract. Following subcutaneous injection of the clinical dose (1.6 mg), peak plasma concentrations are achieved within approximately 2 hours. The elimination half-life has been reported at approximately 2 hours in healthy volunteers, with a volume of distribution of roughly 14 liters. The peptide is cleared through proteolytic degradation rather than renal filtration, and metabolites are amino acids recycled into normal protein pools. These pharmacokinetic parameters are consistent with the twice-weekly dosing schedule used in hepatitis B clinical trials, as the biological effects on immune cell function appear to persist beyond the brief systemic exposure window.

Approved indications and reported dose ranges

Not medical advice. These are ranges reported in research literature, not personalized recommendations. Consult your physician.

Zadaxin (thymalfasin) is approved in jurisdictions including China, Italy, the Philippines, and Pakistan for chronic hepatitis B at a dose of 1.6 mg subcutaneously twice weekly for 6–12 months, and for chronic hepatitis C as an adjunct to interferon at the same dose and schedule. The approved product is a lyophilized powder for injection supplied in 1.6 mg single-use vials. These doses and indications are from approved product labeling in the relevant markets; they do not constitute FDA approval for therapeutic use in the United States. In US research literature, Tα1 has been studied at 1.6 mg twice weekly (the internationally approved hepatitis dose) and at 6 mg twice weekly in some oncology trials.

Storage and handling

The commercial Zadaxin product is stored at 2–8 °C (refrigerated) as a lyophilized powder; it does not require frozen storage under approved labeling. Once reconstituted with sterile water, the solution should be used immediately and any unused portion discarded — it is formulated as a single-use product. Research-grade thymosin alpha-1 lyophilate should be stored at −20 °C, protected from moisture and light. Reconstituted solutions should be kept at 2–8 °C and used within 7–14 days. The peptide is susceptible to oxidation at the methionine-like side chains and should not be exposed to strong oxidizing agents.

What thymosin alpha-1 is NOT

Thymosin alpha-1 is frequently confused with thymosin beta-4 (TB4) or its fragment TB-500, both of which are covered separately on Pepticker. These are unrelated peptides: thymosin beta-4 is a 43-amino acid actin-sequestering protein with proposed wound-healing and cardiac effects; thymosin alpha-1 is a 28-amino acid thymic immune modulator with an entirely different sequence, mechanism, and clinical evidence base. The two peptides share the 'thymosin' name because both were isolated from bovine thymosin fraction 5 in the 1970s, but they are functionally and structurally distinct. Thymosin alpha-1 is also not thymalin (another thymic peptide used in Russia; covered separately on Pepticker under 'thymalin'). Additionally, Tα1 is not an FDA-approved treatment in the United States; its orphan-drug designations represent incentive designations, not approval.

References

Key sources underlying this article include the hepatitis C combination trial (Zeuzem et al., Hepatology 1998; PMID 9537454), the Zadaxin hepatitis B meta-analysis overview (PubMed 15992078), the comprehensive literature review (PMC7747025), and the mechanism and clinical experience review by Tuthill et al. (Ann N Y Acad Sci, 2010; PMID 20738318). The SciClone Zadaxin product information and FDA orphan-drug database provide regulatory status details.